
MPM BioImpact
Venture capital firm · Cambridge, MA · Boston ↗
MPM BioImpact (MPM Capital) invests in and builds private and public companies across the drug development process - including company creation such as Aktis Oncology and Orna Therapeutics - with the goal of transforming scientific breakthroughs into life-saving medicines.
Tier reflects published scale and track-record signals. It is not a rating of the firm as a partner.
This profile is unclaimed. Built from public sources. If you're a partner or employee at MPM BioImpact, you can claim it.
Claim this profileHow claiming worksKey numbers
Assets under management
$3B
Latest fund
Oncology Impact Fund 2 (OIF 2)$850M · 2021
Funds
LAST CHECKED NOV 2026
Check size
LAST CHECKED NOV 2026
Stages
No public record
Sectors
BiotechnologyOncology
FIGURES ARE AS PUBLISHED IN THE CATALOG RECORD 1 · PER-FIGURE AS-OF DATES ARE NOT YET IN THE CATALOG
Track record
Hits
- Orna Therapeuticsacquired
The firm's site states 'We built Orna Therapeutics' and that in 2026 Orna was acquired by Lilly for up to $2.4 billion.
Source: mpmbioimpact.com
Misses
Track record
Partners 14
Briggs MorrisonEntrepreneur Partner
Board seats
No public record
Kristen LaguerrePartner
Board seats
No public record
Rami RahalPartner
Board seats
No public record
Brian ShusterEntrepreneur Partner
Board seats
2 current
Detlev BiniszkiewiczPartner
Board seats
1 current
Elizabeth StonerEntrepreneur Partner
Board seats
3 current
Matthew RodenEntrepreneur Partner
Board seats
1 on record
Aparna ParikhEntrepreneur Partner
Board seats
No public record
Andrew ScharenbergEntrepreneur Partner
Board seats
No public record
Ansbert GadickeManaging Partner
Board seats
No public record
Christiana BardonManaging Partner
Board seats
No public record
Frank NeumannEntrepreneur Partner
Board seats
No public record
Show all 14 partners
Pankaj BhargavaEntrepreneur Partner
1 current
Todd FoleyChairman
7 current
Reputation
No reputation score — basis not established for this firm.
Contact
Published sources only
Published contact
- Website
- mpmbioimpact.com
- [email protected]
- linkedin.com
Published sources only
GlassVC lists only contact information the firm or its sources have published. We do not list personal emails, direct lines, or private addresses.
SOURCE: FIRM WEBSITE, AS PUBLISHED 2
What founders say
Founder-submitted · Verified identity and relationship
No founder reviews yet
Be the first founder to share your experience with MPM BioImpact. Reviews come from founders whose identity and relationship have been verified.
Write the first reviewMethodology
Tier basis — Grouped by disclosed AUM of $3B (AUM-band grouping — full tier basis pending in the catalog). Tier reflects published scale and track-record signals. It is not a rating of the firm as a partner.
Figures are shown as published; conflicting figures are never averaged. Review dimension scores appear only once three founders have reviewed this firm; profiles below that threshold do not appear in rated lists.
The catalog does not yet carry per-figure citations or as-of dates: every figure on this page traces to the catalog record listed below, and that limit is stated rather than papered over. Corrections with a source: Suggest a correction.
Source record 2
- [1]
DATABASE · GlassVC catalog — Catalog record for MPM BioImpact — provenance: GlassVC catalog census, November 2026
↩ cites: AUM · Check size · Founded · HQ · Stages · Sectors · Funds · Track record · Reputation
- [2]
FIRM SITE · MPM BioImpact — Firm website, as published by the firm
PROFILE BUILT FROM PUBLIC SOURCES · 2 CATALOG SOURCES · LAST CHECKED NOV 2026
